Clinical Trial Update: Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fed Conditions [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study of fixed-dose combination tablets containing lisinopril 20 mg and hydrochlorothiazide 25 mg completed under fed conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Lisinopril/Hydrochlorothiazide fixed-dose combination tablet (20 mg/25 mg) (Lisinopril and Hydrochlorothiazide)

Snippet

Sponsor: IPCA Laboratories Ltd. | Conditions: Fed | Phase 1 | Status: COMPLETED